Cited by 169Bone health and osteoporosis researchBone health and treatmentsMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Denosumab: A Review in Postmenopausal Osteoporosis

Deeks, Emma D.·2018·Drugs & Aging

Open this paper in CoChat — free account

Abstract

Denosumab (Prolia ® ; Pralia ® ) is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The drug is administered via subcutaneous injection once every 6 months and is approved for various indications, including the treatment of postmenopausal (PM) women with osteoporosis at increased/high risk of fracture or failure/intolerance of other osteoporosis therapies (indications featured in this review). Denosumab showed benefit in several phase 3 or 4 studies in PM women with osteoporosis or low bone mineral density (BMD), including the pivotal 3-year double-blind FREEDOM trial and its 7-year open-label extension. Denosumab reduced the risk of vertebral, nonvertebral and hip fractures and increased BMD across skeletal sites versus placebo in FREEDOM, with these benefits maintained over up to 10 years' therapy in the extension. The drug was also more effective in improving BMD than bisphosphonates, including in women switched from a bisphosphonate regimen, in 1-year trials; however, whether these differences translate into differences in anti-fracture efficacy is unclear. Denosumab was generally well tolerated over up to 10 years' treatment, although an increased risk of multiple vertebral fractures was observed after discontinuation of the drug. Thus, denosumab is a key treatment option for PM women with osteoporosis who have an increased/high risk of fracture or failure/intolerance of other osteoporosis therapies, although the potential for multiple verte…

Integrity signals

Registry

Crossref · 10.1007/s40266-018-0525-7

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Postmenopausal Osteoporosis
Black, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,790
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996
Postmenopausal osteoporosis
Eastell, R., O’Neill, T. W., Hofbauer, L. C., Langdahl, B. L., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 877
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Cummings, S. R., Ferrari, S., Eastell, R., Gilchrist, N. L., Jensen, J. B., McClung, M. R., Roux, C., Törring, O., Valter, I., Wang, A. T., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3337 · Cited by 753
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y., Grazette, L. P., Martín, J. S., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 634
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Brown, J. P., Prince, R. L., Deal, C. L., Recker, R. R., Kiel, D. P., de Gregorio, L. H., Hadji, P., Hofbauer, L. C., Álvaro‐Gracia, J. M., Wang, H., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0809010 · Cited by 616
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Tsourdi, E. A., Langdahl, B. L., Cohen-Solal, M. E., Aubry‐Rozier, B., Eriksen, E. F., Guañabens, N., Obermayer-Pietsch, B. M., Ralston, S. H., Eastell, R., & Zillikens, M. C. (2017) · Bone · doi:10.1016/j.bone.2017.08.003 · Cited by 508
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 491
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
Kendler, D. L., Roux, C., Benhamou, C. L., Brown, J. P., Lillestol, M. J., Siddhanti, S. R., Man, H., Martín, J. S., & Bone, H. G. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090716 · Cited by 455
Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL
Kostenuik, P. J., Nguyen, H. Q., McCabe, J. G., Warmington, K. S., Kurahara, C., Sun, N., Chen, C., Li, L. Z., Cattley, R., Van, G. Y., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081112 · Cited by 448
Effects of denosumab on fracture and bone mineral density by level of kidney function
Jamal, S. A., Ljunggren, Ö., Stehman‐Breen, C. O., Cummings, S. R., McClung, M. R., Goemaere, S., Ebeling, P. R., Franek, E., Yang, Y., Egbuna, O. I., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.403 · Cited by 357
Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate
Seeman, E., Delmas, P. D., Hanley, D. A., Sellmeyer, D. E., Cheung, A. M., Shane, E. J., Kearns, A. E., Thomas, T., Boyd, S. K., Boutroy, S., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.81 · Cited by 293
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
Eastell, R., Christiansen, C., Grauer, A., Kutílek, Š., Libanati, C. R., McClung, M. R., Reid, I. R., Resch, H., Siris, E. S., Uebelhart, D., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.251 · Cited by 261
Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
Reid, I. R., Miller, P. D., Brown, J. P., Kendler, D. L., Fahrleitner‐Pammer, A., Valter, I., Maasalu, K., Bolognese, M. A., Woodson, G. C., Bone, H. G., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.149 · Cited by 254
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
Miller, P. D., Pannacciulli, N., Brown, J. P., Czerwinski, E. J., Nedergaard, B. S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J., Singer, A. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1801 · Cited by 244
Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk
Boonen, S., Adachi, J. D., Man, Z., Cummings, S. R., Lippuner, K., Törring, O., Gallagher, J. C., Farrerons, J., Wang, A., Franchimont, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2784 · Cited by 224
Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
Nakamura, T., Matsumoto, T., Sugimoto, T., Hosoi, T., Miki, T., Gorai, I., Yoshikawa, H., Tanaka, Y., Tanaka, S., Sone, T., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4175 · Cited by 171
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
Roux, C., Hofbauer, L. C., Ho, P., Wark, J. D., Zillikens, M. C., Fahrleitner‐Pammer, A., Hawkins, F. G., Micaëlo, M., Minisola, S., Παπαϊωάννου, Ν., et al. (2013) · Bone · doi:10.1016/j.bone.2013.10.006 · Cited by 158
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis
McClung, M. R., Boonen, S., Törring, O., Roux, C., Rizzoli, R., Bone, H. G., Benhamou, C.-L., Lems, W. F., Minisola, S., Halse, J., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.536 · Cited by 157
Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
Brown, J. P., Roux, C., Törring, O., Ho, P., Jensen, J. B., Gilchrist, N. L., Recknor, C. P., Austin, M., Wang, A., Grauer, A., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1808 · Cited by 149
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX
McCloskey, E. V., Johansson, H., Odén, A., Austin, M., Siris, E. S., Wang, A., Lewiecki, E. M., Lorenc, R. S., Libanati, C. R., & Kanis, J. А. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1606 · Cited by 144
Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy
Recknor, C. P., Czerwinski, E. J., Bone, H. G., Bonnick, S. L., Binkley, N., Palacios, S., Moffett, A. H., Siddhanti, S. R., Ferreira, I., Ghelani, P., et al. (2013) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e318291718c · Cited by 133
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
Anagnostis, P. G., Paschou, S. Α., Mintziori, G., Ceauşu, I., Depypere, H. T., Lambrinoudaki, I. V., Mueck, A. O., Pérez-López, F. R., Rees, M., Senturk, L. M., et al. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.008 · Cited by 129
Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing
Adami, S., Libanati, C. R., Boonen, S., Cummings, S. R., Ho, P., Wang, A., Siris, E. S., & Lane, J. M. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.00774 · Cited by 124
Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis
Sutjandra, L., Rodriguez, R. D., Doshi, S., Ma, M., Peterson, M. C., Jang, G. R., Chow, A. T., & Ruixo, J. J. P. (2011) · Clinical Pharmacokinetics · doi:10.2165/11594240-000000000-00000 · Cited by 121
Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
Zanchetta, M. B., Boailchuk, J., Massari, F., Silveira, F., Bogado, C., & Zanchetta, J. R. (2018) · Osteoporosis International · doi:10.1007/s00198-017-4242-6 · Cited by 119
Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
Keaveny, T. M., McClung, M. R., Genant, H. K., Zanchetta, J., Kendler, D. L., Brown, J. P., Goemaere, S., Recknor, C. P., Brandi, M. L., Eastell, R., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2024 · Cited by 117
Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
Karlsson, L. K., Lundkvist, J., Psachoulia, E., Intorcia, M., & Ström, O. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3253-4 · Cited by 99
Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study
Hadji, P., Παπαϊωάννου, Ν., Gielen, E., Tepie, M. F., Zhang, E., Frieling, I., Geusens, P., Makras, P., Resch, H., Möller, G., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3164-4 · Cited by 93
Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy study
Brown, J. P., Dempster, D. W., Ding, B., Dent-Acosta, R. E., Martín, J. S., Grauer, A., Wagman, R. B., & Zanchetta, J. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.448 · Cited by 86
Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis
Zebaze, R., Libanati, C. R., McClung, M. R., Zanchetta, J., Kendler, D. L., Høiseth, A. D., Wang, A., Ghasemzadeh, A., & Seeman, E. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2855 · Cited by 83
Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis
Poole, K. E. S., Treece, G. M., Gee, A. H., Brown, J. P., McClung, M. R., Wang, A., & Libanati, C. R. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2325 · Cited by 83
Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
Parthan, A., Kruse, M., Yurgin, N., Huang, J., Viswanathan, H. N., & Taylor, D. C. A. (2013) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0047-8 · Cited by 81
Denosumab Significantly Increases DXA BMD at Both Trabecular and Cortical Sites: Results From the FREEDOM Study
Bolognese, M. A., Teglbjærg, C. S., Zanchetta, J., Lippuner, K., McClung, M. R., Brandi, M. L., Høiseth, A. D., Lakatos, P. L., Moffett, A. H., Lorenc, R. S., et al. (2012) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2012.02.006 · Cited by 64
Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis
Beaudoin, C., Jean, S., Bessette, L., Ste‐Marie, L., Moore, L., & Brown, J. P. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3607-6 · Cited by 63
Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
Sugimoto, T., Matsumoto, T., Hosoi, T., Miki, T., Gorai, I., Yoshikawa, H., Tanaka, Y., Tanaka, S., Fukunaga, M., Sone, T., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2964-2 · Cited by 62
Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis
Lin, T., Wang, C., Cai, X.-Z., Zhao, X., Shi, M.-M., Ying, Z., Yuan, F., Guo, C., & Yan, S.-G. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02806.x · Cited by 62
Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology
Zysset, P. K., Pahr, D. H., Engelke, K., Genant, H. K., McClung, M. R., Kendler, D. L., Recknor, C. P., Kinzl, M., Schwiedrzik, J. J., Museyko, O., et al. (2015) · Bone · doi:10.1016/j.bone.2015.06.025 · Cited by 57
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass
Kendler, D. L., Bessette, L., Hill, C., Gold, D. T., Horne, R., Varon, S. F., Borenstein, J. E., Wang, H., Man, H., Wagman, R. B., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1023-x · Cited by 54
Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium
Fahrleitner‐Pammer, A., Παπαϊωάννου, Ν., Gielen, E., Tepie, M. F., Toffis, C., Frieling, I., Geusens, P., Makras, P., Boschitsch, E., Callens, J., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0351-2 · Cited by 54
Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis
Zhang, L., Pang, Y., Shi, Y., Xu, M., Xu, X., Ju, Z., Ji, L., & Zhao, D. (2015) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000466 · Cited by 52
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis
Simon, J. A., Recknor, C. P., Moffett, A. H., Adachi, J. D., Franek, E., Lewiecki, E. M., McClung, M. R., Mautalén, C., Ragi-Eis, S., Nicholson, G. C., et al. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318267f909 · Cited by 43
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis
Ström, O., Jönsson, B., & Kanis, J. A. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2115-6 · Cited by 35
Denosumab Densitometric Changes Assessed by Quantitative Computed Tomography at the Spine and Hip in Postmenopausal Women With Osteoporosis
McClung, M. R., Zanchetta, J., Høiseth, A. D., Kendler, D. L., Yuen, C. K., Brown, J. P., Stonkus, S., Goemaere, S., Recknor, C. P., Woodson, G. C., et al. (2012) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2012.02.014 · Cited by 35
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada
Chau, D., Becker, D. L., Coombes, M., Ioannidis, G., Adachi, J. D., & Goeree, R. A. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.737393 · Cited by 30
Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial
Silverman, S. L., Viswanathan, H. N., Yang, Y., Wang, A., Boonen, S., Ragi-Eis, S., Fardellone, P., Gilchrist, N. L., Lips, P. T. A. M., Nevitt, M. C., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1720-0 · Cited by 29
Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
Palacios, S., Kalouche-Khalil, L., Rizzoli, R., Zapalowski, C., Resch, H., Adachi, J. D., Gallagher, J. C., Feldman, R. G., Kendler, D. L., Wang, A., et al. (2015) · Climacteric · doi:10.3109/13697137.2015.1045484 · Cited by 26
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
Darbà, J., Kaskens, L., Sorio, F., & Löthgren, M. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s78349 · Cited by 21
Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program
Παπαϊωάννου, Α., Khan, A. A., Belanger, A., Bensen, W., Kendler, D. L., Theoret, F., Amin, M., Brekke, L. N., Erdmann, M., Walker, V., et al. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1053049 · Cited by 18
A clinical therapeutic protein drug–drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis
Jang, G. R., Kaufman, A., Lee, E. W., Hamilton, L. J., Hutton, S., Egbuna, O. I., & Padhi, D. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.33 · Cited by 16
The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug
de Waure, C., Specchia, M. L., Cadeddu, C., Capizzi, S., Capri, S., Pietro, M. L. D., Veneziano, M. A., Gualano, M. R., Kheiraoui, F., Torre, G. L., et al. (2014) · BioMed Research International · doi:10.1155/2014/975927 · Cited by 13
Mixed Treatment Comparison to Rank Antiresorptive Agents In Preventing New Non Vertebral Fractures In Postmenopausal Osteoporosis
Massafra, U., Integlia, D., Broccoli, S., & Migliore, A. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.2260 · Cited by 4
Effects of Denosumab (Dmab) on bone matrix mineralization: results from the phase 3 FREEDOM trial
Dempster, D. W., Brown, J. P., Yue, S. V., Farlay, D., Rizzo, S., Song, J. Z., Wang, A., Wagman, R. B., & Boivin, G. (2016) · Bone Abstracts · doi:10.1530/boneabs.5.oc3.2 · Cited by 1

Research works printed but not linked: 2

Zhang Y, Zhang L, Li S, et al. Effect of denosumab, a fully human monoclonal antibody to RANKL, on bone mineral density and fractures: a meta-analysis. Int J Clin Exp Med. 2017;10(4):5931–40.
Insinga RP. Administration costs of denosumab and zoledronic acid for postmenopausal osteoporosis. Am J Pharm Benefits. 2016;8(3):e42–7.

Sorted by citations

Current Status of the Diagnosis and Management of Osteoporosis
Aibar-Almazán, A., Voltes-Martínez, A., Castellote-Caballero, Y., Afanador-Restrepo, D. F., Carcelén-Fraile, M. D. C., & López-Ruiz, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169465 · Cited by 412
Osteoporosis pathogenesis and treatment: existing and emerging avenues
Liang, B., Burley, G., Lin, S., & Shi, Y. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00371-3 · Cited by 250
The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis
Seely, K. D., Kotelko, C. A., Douglas, H. E., Bealer, B., & Brooks, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179452 · Cited by 209
RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M., & Fabbri, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1001-2 · Cited by 180
Insights and implications of sexual dimorphism in osteoporosis
Zhang, Y., Xie, N., Sun, X., Nice, E. C., Liou, Y., Huang, C., Zhu, H., & Shen, Z. (2024) · Bone Research · doi:10.1038/s41413-023-00306-4 · Cited by 164

See all 169

Authors: Deeks, E. D.
Affiliations: Springer Nature (New Zealand) (NZ)
Corresponding author: Deeks, Emma D.
Venue: Drugs & Aging
Publisher: Springer Science and Business Media LLC
Published: 2018-02
Volume: 35
Issue: 2
Pages: 163-173
ISSN: 1170-229X (ISSN-L)
1179-1969
DOI: 10.1007/s40266-018-0525-7
OpenAlex: W2792392055
Cited by: 169
References: 55
Citations by year: 2026: 7 · 2025: 23 · 2024: 16 · 2023: 22 · 2022: 32 · 2021: 37 · 2020: 19 · 2019: 10 · 2018: 3
FWCI: 18.74
Type: journal article
Language: en
Update notices: correction (2018-03-09)
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Drugs & Aging (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords: denosumab, postmenopausal osteoporosis, RANKL, monoclonal antibodies, fracture risk, vertebral fractures, hip fracture, osteopenia, FREEDOM trial, drug discontinuation, adverse events, long-term treatment
MeSH terms: Denosumab, Aged, Clinical Trials as Topic, Female, Humans, Bone Density, Osteoporosis, Postmenopausal, Treatment Outcome, Bone Density Conservation Agents, Fractures, Bone, RANK Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Denosumab: A Review in Postmenopausal Osteoporosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks